scholarly journals Transcatheter aortic valve implantation in the United States: Predictors of early hospital discharge

2017 ◽  
Vol 30 (2) ◽  
pp. 149-155 ◽  
Author(s):  
Sagar Mallikethi-Reddy ◽  
Emmanuel Akintoye ◽  
Tesfaye Telila ◽  
Rajeev Sudhakar ◽  
Kavyashri Jagadeesh ◽  
...  
2015 ◽  
Vol 116 (12) ◽  
pp. 1910-1915 ◽  
Author(s):  
Luke K. Kim ◽  
Robert M. Minutello ◽  
Dmitriy N. Feldman ◽  
Rajesh V. Swaminathan ◽  
Geoffrey Bergman ◽  
...  

Circulation ◽  
2018 ◽  
Vol 138 (Suppl_1) ◽  
Author(s):  
Francis Kuttamperoor ◽  
Srikanth Yandrapalli ◽  
Varunsiri Atti ◽  
Sisir Siddamsetti ◽  
William Frishman

Background: Infectious endocarditis (IE) is a known complication after transcatheter aortic valve implantation (TAVI). Available data suggest that IE was infrequent after TAVI but was associated with substantial mortality. We sought to determine the 6-month incident rates and outcomes of this complication after TAVI in the United States representative patient population. Methods: A weighted sample of adult patients who underwent TAVI and survived to discharge were identified in the Nationwide Readmissions Database January to June 2014 using appropriate ICD-9 codes. Among these patients, readmissions within 180-days in which IE was diagnosed were identified. Microbiology, complications, valvular procedural utilization, and mortality with IE were the outcomes studied. Results: Of 7,834 patients (mean age 81 years, 52% men) who underwent TAVI during the study period, 61 patients (0.8%; mean age 79 years, 58% men) had IE within 180 days form discharge. Median day to developing IE was 79 days [interquartile range 49-124 days]. Septicemia was present in 43 patients (71%) of which 15 (24%) developed septic shock. Gram positive bacteremia was frequent with 13 patients (21%) having Streptococcal bacteremia, and 12 (19%) with Staphylococcal bacteremia. Gram negative organisms were identified in 4%. Heart failure developed in 46 patients (75%), respiratory failure in 12 (20%), and acute kidney injury in 18 (29%). Concomitant pneumonia was present in 8 patients (13%). A valvular intervention was not performed in any of the 61 patients and 13 patients (22%) died in-hospital after IE diagnosis. Conclusions: Nearly 8 out of every 1000 patients undergoing TAVI developed IE within 6 months post-procedure. IE post TAVI was most commonly caused by gram positive bacteria and was associated with very high rates of multi-system complication. A valvular intervention was not performed in these sick patients with IE, and 1 out of 5 patient who developed IE died.


Heart ◽  
2021 ◽  
pp. heartjnl-2021-319179
Author(s):  
Sahoor A Khan ◽  
Suzanne J Baron

Approximately 2% of people between the ages of 70 and 83 suffer from moderate or greater aortic regurgitation (AR) in the United States. Left untreated, this disease is progressive and fatal; however, up to 8% of patients with AR, who meet the criteria for surgical intervention, do not receive treatment. As such, there is a pressing need to address the lack of treatment options for the thousands of patients with AR who meet a class I indication for aortic valve replacement but who still do not receive surgery. The advent of transcatheter aortic valve implantation (TAVI) has significantly altered the paradigm of treatment for valvular heart disease and is now a well-established therapeutic option for patients with severe aortic stenosis. While transcatheter devices dedicated for the treatment of AR are under investigation, they are not commercially available at this time. Nevertheless, there is a growing body of data that demonstrate acceptable safety and efficacy for the off-label use of current TAVI devices for the treatment of severe AR. Given the dearth of treatment options for inoperable patients with severe AR, available TAVI devices should be considered for this patient population.


Sign in / Sign up

Export Citation Format

Share Document